Showing posts with label Biomarkers Market. Show all posts
Showing posts with label Biomarkers Market. Show all posts

ReportsandReports – Global Cancer Biomarkers Market (2010 - 2015)

Browse the complete Report on: Global Cancer Biomarkers Market (2010 - 2015)

Browse All MarketsandMarkets Market Research Reports

Cancer is recognized as a major cause of mortality world over; accounting for 7.4 million (or 13%) of all deaths in 2004. The WHO estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015. The rising prevalence of the disease forms one of the major factors driving the growth of the oncology biomarkers market.
Biomarker are chemical, physical, or biological parameters that can be used to indicate disease states. Oncology biomarkers facilitate high-speed, non-invasive cancer diagnosis; and are believed to enhance early cancer detection and screening. The demand for oncology biomarkers is also increasing because of their ability to trace the exact type of cancer and to target patient-specific molecular structure.

The oncology biomarkers market offers high-growth opportunities with the numerous initiatives to encourage biomarker-based cancer treatment. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) ) are have taken an active interest in the field, especially with the declining success to failure rate of oncology drugs

Market Estimates and Forecasts
The report categorizes the Global oncology biomarkers market as follows:
Oncology biomarkers discovery market
Oncology biomarkers diagnostics market
Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 15 company profiles for each of its sub-segments.

What makes our reports unique?
We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered
Which are the high-growth segments/cash cows and how is the market segmented in terms of oral drugs, injectables?
What are market estimates and forecasts; which markets are doing well and which are not?
Where are the gaps and opportunities; what is driving the market?
Which are the key playing fields? Which are the winning edge imperatives?
How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis
The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/

Original Source: Global Cancer Biomarkers Market
Buy Now: Research

Read More
Posted by Unknown on
categories: , , , , , , , , , |

ReportsandReports - Biomarkers in Late Stage Clinical Trials: Applications, opportunities and activities of leading players



The pharmaceuticals and biotechnology sectors are currently facing increasing time and cost issues related to clinical trials in drug discovery. The cost of developing a new drug can reach $2 billion; clinical trials, regulatory approval and subsequent launch may take up to a decade.

Biomarkers reduce the attrition rate of late stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of the clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of the clinical trial, and help researchers complete drug development process at a faster pace.

This report reviews various biomarker technologies and therapy area applications. Market drivers and restraints are viewed in the context of biomarker activity of leading innovator companies as well as contract research organizations.

Key features of this report
  • The report analyzes revenues of late stage biomarker technology and services in North America, Europe, Asia and rest of the world.
  • Provides key market drivers and restraints of the biomarker market.
  • Covers microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services
  • Provides patent analysis with respect to competitors and geography.
Scope of this report
  • Understand and evaluate the growth potential of emerging technologies.
  • Understand biomarker activity in clinical trials of leading market players.
  • Gain knowledge about the relative importance of the biomarker late stage clinical trials technologies in the next five years for investment opportunities.
  • Learn which therapy areas leading market players in the late stage biomarker clinical trials market.
  • Determine the collaborations and partnerships of the major market players.
Key Market Issues
  • The pharmaceutical and biotech sectors are currently facing increasing duration and cost issues related to clinical trials in drug discovery.
  • Funding from government sources such as the National Institutes of Health (NIH) has not increased significantly over the last few years.
  • Late stage failures are much more expensive than early ones.
  • The rising demand for better safety data has put a considerable amount of regulatory and economic pressure on pharmaceutical companies.
  • The current average approval rate of cancer drugs is as low as 5%, while the development period can reach 15 years.
  • More than 50% of clinical trials fail in Phase III due to a host of reasons, greater disease complexity, stiffer clinical endpoints, and the inability of the data to prove drug effectiveness.
Key findings from this report
  • The biomarkers in late stage clinical trials market is largest in North American and European region, with Europe having the second largest market.
  • North America constitutes the major market share with the immunoassay, flow cytometry and GC/MS and LC/MS having high market growth.
  • Caprion proteomics, Applied BioSystems, BG Medicine, Covance, Eli Lilly, Pfizer and Astra Zeneca are some of the major companies engaged in collaborative partnerships in the past three years.
  • A number of market players have formed strategic alliances for the development and sharing of technology for biomarker applications in the late stage clinical trials.
  • Pharmaceutical companies are focusing mainly on cancer biomarkers for use in late stage (Phase III and IV) clinical trials.
Key questions answered
  • How is the biomarker late stage clinical trials market segmented and what will growth be to 2014?
  • What are the major technologies that have emerged such as microarrays, PCR, LC/MS and GC/MS?
  • In which areas are the companies focusing while forming strategic alliances with other industrial players?
  • What is the competitive landscape and what is the strategic focus of innovator companies, CROs and biomarker specialists?
  • What applications are pharmaceutical companies focusing on while conducting late stage biomarker clinical trials?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , |